Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Arrowhead Pharmaceuticals, Inc. - Common Stock (NQ: ARWR )

15.07 -0.70 (-4.44%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arrowhead Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers CinCor Pharma, Inc. (NASDAQ: CINC) shares jumped 137% to $27.93 after AstraZeneca announced it will acquire the company for $26 per share in cash. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
HC Wainwright & Co. Maintains Buy Rating for Arrowhead Pharmaceuticals: Here's What You Need To Know
Via Benzinga
Arrowhead Pharmaceuticals's Return On Capital Employed Overview
Via Benzinga
Analyst Ratings for Arrowhead Pharmaceuticals
Via Benzinga
Earnings Preview For Arrowhead Pharmaceuticals
Via Benzinga
Arrowhead Pharmaceuticals Reports Underwhelming Data From Inherited Disease Study
Via Benzinga
Why Arrowhead Pharmaceuticals Stock Is Diving Today
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) shares are down 20% Monday after the company announced topline results from the SEQUOIA Phase 2 study of fazirsiran in patients with 
Via Benzinga
CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks
Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too. 
Via Investor's Business Daily
Arrowhead Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
Arrowhead Pharmaceuticals to Present Topline Data from the Phase 2 SEQUOIA Study Evaluating Fazirsiran and Describe Design for Planned Phase 3 Study
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Announces $25 Million Milestone Payment from Amgen
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Announces First Patient Enrolled in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Surges After Hinting At A Midstage Win In Liver Disease
The company says it plans soon to present Phase 2 results and its Phase 3 study design. 
Via Investor's Business Daily
Arrowhead Pharmaceuticals Reports Fiscal 2022 Year End Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Earnings Scheduled For November 28, 2022
Companies Reporting Before The Bell • Pinduoduo (NASDAQ:PDD) is projected to report quarterly earnings at $0.65 per share on revenue of $4.31 billion. 
Via Benzinga
Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conferences
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Year End Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Royalty Pharma Agrees to Acquire Royalty Interest in Olpasiran From Arrowhead for $250 million and Future Milestones
From Royalty Pharma plc
Via GlobeNewswire
Arrowhead Sells Royalty Interest in Olpasiran to Royalty Pharma for $250 Million and Future Milestones
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Presents New Phase 2 Data at AHA 2022 on Cardiometabolic Pipeline
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals to Present Interim Phase 2 Clinical Data at AHA 2022 on SHASTA-2 Study of ARO-APOC3 and ARCHES-2 Study of ARO-ANG3
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022
Upgrades 
Via Benzinga
Arrowhead Pharmaceuticals to Participate in Upcoming September 2022 Conferences
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MMP7 for Idiopathic Pulmonary Fibrosis
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
What 7 Analyst Ratings Have To Say About Arrowhead Pharmaceuticals
  Analysts have provided the following ratings for Arrowhead Pharmaceuticals (NASDAQ:ARWR) within the last quarter: 
Via Benzinga
Arrowhead Pharmaceuticals: Q3 Earnings Insights
Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported its Q3 earnings results on Thursday, August 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Arrowhead Pharmaceuticals Reports Fiscal 2022 Third Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.